LOXO-305 free base · Synonyms: Pirtobrutinib

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.

For research use only. Not for human or veterinary use.

Target Btk

Research area Cancer

Purity HPLC>98%,ee>99% Stock Inquire

Data Sheet SDS COA

LOXO-305 structure

CAS No.: 2101700-15-4

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
500 mg	USD 480.00	BP-01972-500mg	In stock	Get quote
1 g	USD 680.00	BP-01972-1g	In stock	Get quote
5 g	Inquire	BP-01972-5g	Inquire	Inquire

Custom Size Bulk Inquiry

Description

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.

Biological activity

In Vitro Pirtobrutinib potently inhibits both wild-type BTK and BTK C481S-mediated kinase activity with nanomolar potency. Pirtobrutinib inhibits WT BTK (Y223) autophosphorylation with an IC50 of 3.68 nM. Pirtobrutinib inhibits BTK C481S Y223, C481T Y223, and C481R Y223 autophosphorylation with IC50s of 8.45, 7.23, and 11.73 nM, respectively.

Identifiers

SMILES: O=C(C1=C(N)N([C@@H](C)C(F)(F)F)N=C1C2=CC=C(CNC(C3=CC(F)=CC=C3OC)=O)C=C2)N
InChIKey: FWZAWAUZXYCBKZ-NSHDSACASA-N

Specifications

MW (average): 479.4275
Formula: C₂₂H₂₁F₄N₅O₃
CAS No.: 2101700-15-4
Physical state: Solid
Color: White to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4°C, stored under nitrogen; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 50 mg/mL

Documents

References

[1]. Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644.

Same target

Search Btk

Same research area

Search Cancer